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Purpose
Within a prospective observational study, we measured
adjustment of methadone doses and responses to treat-
ment after once-daily raltegravir (RGV)-based highly
active antiretroviral therapy (HAART) was initiated in
injection drug users (IDUs).
Methods
We evaluated HIV-infected IDUs attending an inner city
clinic in Vancouver who were receiving RGV-based
HAART and methadone within a directly observed ther-
apy program. Follow-up was according to clinical stan-
dards, with changes in methadone dose being made as
required to achieve clinical stabilization within the first
month of HAART. The change in methadone dosing
associated with the initiation of HAART was calculated
as the difference between the post- and pre-HAART
methadone doses. The most recent on treatment CD4
cell count and HIV plasma viral load were used to eval-
uate HAART efficacy after initiation of therapy.
Results
The study included 34 subjects (9 female) with a median
follow-up period of 16.5 months. All patients were treat-
ment experienced and co-infected with hepatitis C virus.
Most patients received RGV-based HAART along with
emtricitabine and tenofovir( n = 1 6 )o rl a m i v u d i n ea n d
abacavir (n=9). At baseline, the mean methadone dose,
mean CD4 cell count and median plasma viral load
w e r e9 7 . 4m g / d a y ,2 8 6c e l l s / m m
3 and 243 copies/mL,
respectively. At month 3, the mean methadone dose was
97.9 mg/day with the observed mean methadone dose
change from baseline being 0.4 mg/day (p=NS). In these
patients, 7 (21%) required increases, 8 (24%) required
decreases, while 19 (56%) required no change in daily
methadone dose from baseline. At most recent follow-
up, the mean CD4 cell count was 355 cells/mm
3 while
virologic suppression (HIV RNA <50 and <400 copies/
mL) was achieved in 23 (68%) and 31 (91%) of patients
receiving RGV-based therapy.
Conclusions
Lack of drug interactions with methadone and improved
immunologic and virologic responses support the use of
once-daily RGV-based HAART in this vulnerable
population.
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